We are live on
!
Find out more
PCA
Private Capital Advisors Portfolio holdings
AUM
$1.14B
1-Year Est. Return
48.66%
This Fund
S&P 500
This Quarter
Est. Return
+10.64%
1 Year Est. Return
+48.66%
3 Year Est. Return
+137.63%
5 Year Est. Return
+227.94%
10 Year Est. Return
+772.14%
AUM
$269M
AUM Growth
–
Cap. Flow
+$264M
Cap. Flow
% of AUM
98.02%
Top 10 Holdings %
Top 10 Hldgs %
27.65%
Holding
112
New
112
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celldex Therapeutics
CLDX
|
+$10.8M |
| 2 |
RH
RH
|
+$10.3M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$7.56M |
| 4 |
Apple
AAPL
|
+$6.29M |
| 5 |
Enterprise Products Partners
EPD
|
+$6.18M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.57% |
| 2 | Energy | 19.28% |
| 3 | Communication Services | 12.18% |
| 4 | Industrials | 9.72% |
| 5 | Technology | 7.79% |
Similar funds
SC
MIG
PC
RIM
VCP
HGIM
CAM
SIM
Private Capital Advisors's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for Private Capital Advisors, which disclosed 112 positions worth $269M. Its ten largest holdings account for 28% of the portfolio.
Its largest position is Celldex Therapeutics: 54,837 shares worth $12.8M.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, followed by Energy and Communication Services.
- Private Capital Advisors's largest Q2 2013 buy was Celldex Therapeutics: 54,837 shares worth $12.8M.
- Private Capital Advisors's ten largest holdings make up 28% of its $269M portfolio in Q2 2013.
- Private Capital Advisors disclosed 112 positions in Q2 2013, its first 13F filing on record.
Based on Private Capital Advisors's 13F filing for Q2 2013, filed 24 Jul 2013.